In the trial subset of 604 participants not taking other Alzheimer's medications, AR1001 was reported to slow symptom worsening by 31% compared to placebo over one year. [1]
South Korean biotechnology company AriBio announced phase 3 trial results for experimental Alzheimer's drug AR1001 at the 19th Clinical Trials on Alzheimer's Disease conference in Boston, United States. [2] Prof. Dr. A. Oğuz Tanrıdağ emphasized that early specialist assessment improves Alzheimer disease management outcomes. [3] Prof. Dr. A. Oğuz Tanrıdağ stated that retaining old memories perfectly while being unable to recall recent events is a key Alzheimer warning sign. [4]
Prof. Dr. A. Oğuz Tanrıdağ, NPİSTANBUL Hospital neurologist, stated that normal forgetting is distinct from persistent pathological forgetfulness. [5] Across the full trial cohort, AR1001 did not produce statistically reliable benefits for Alzheimer's symptoms. [6] The AR1001 phase 3 trial enrolled 1535 people with early Alzheimer's disease across 13 countries, with participants receiving either 30mg AR1001 or placebo daily for one year. [7]
Prof. Dr. A. Oğuz Tanrıdağ listed time/place disorientation, language difficulty, and impaired daily tasks as early Alzheimer signs. [8]En el subgrupo del ensayo formado por 604 participantes que no tomaban otros medicamentos para el Alzheimer, se reportó que AR1001 ralentizó el empeoramiento de los síntomas en un 31% en comparación con el placebo durante un año. [1]
La empresa biotecnológica surcoreana AriBio anunció los resultados del ensayo de fase 3 del fármaco experimental contra el Alzheimer AR1001 en la 19.ª conferencia de Ensayos Clínicos sobre la Enfermedad de Alzheimer, celebrada en Boston, Estados Unidos. [2] El profesor doctor A. Oğuz Tanrıdağ destacó que la evaluación especializada temprana mejora los resultados del manejo de la enfermedad de Alzheimer. [3] El profesor doctor A. Oğuz Tanrıdağ indicó que conservar perfectamente los recuerdos antiguos mientras no se logran recordar eventos recientes es una señal de alerta clave del Alzheimer. [4]
El profesor doctor A. Oğuz Tanrıdağ, neurólogo del Hospital NPİSTANBUL, señaló que el olvido normal se distingue del olvido patológico persistente. [5] En el conjunto completo de participantes del ensayo, AR1001 no produjo beneficios estadísticamente fiables para los síntomas del Alzheimer. [6] El ensayo de fase 3 de AR1001 reclutó a 1535 personas con Alzheimer en etapa inicial en 13 países. Los participantes recibieron diariamente 30mg de AR1001 o placebo durante un año. [7]
El profesor doctor A. Oğuz Tanrıdağ enumeró la desorientación de tiempo y lugar, las dificultades de lenguaje y la alteración para realizar tareas cotidianas como signos tempranos del Alzheimer. [8]
Proof8 sources · 2 publishers · signed
What this stands on
In the trial subset of 604 participants not taking other Alzheimer's medications, AR1001 was reported to slow symptom worsening by 31% compared to placebo over one year. · Medical Xpress
South Korean biotechnology company AriBio announced phase 3 trial results for experimental Alzheimer's drug AR1001 at the 19th Clinical Trials on Alzheimer's Disease conference in Boston, United States. · Medical Xpress
Prof. Dr. A. Oğuz Tanrıdağ emphasized that early specialist assessment improves Alzheimer disease management outcomes. · Ekonomim
Prof. Dr. A. Oğuz Tanrıdağ stated that retaining old memories perfectly while being unable to recall recent events is a key Alzheimer warning sign. · Ekonomim
Prof. Dr. A. Oğuz Tanrıdağ, NPİSTANBUL Hospital neurologist, stated that normal forgetting is distinct from persistent pathological forgetfulness. · Ekonomim
Across the full trial cohort, AR1001 did not produce statistically reliable benefits for Alzheimer's symptoms. · Medical Xpress
The AR1001 phase 3 trial enrolled 1535 people with early Alzheimer's disease across 13 countries, with participants receiving either 30mg AR1001 or placebo daily for one year. · Medical Xpress
Prof. Dr. A. Oğuz Tanrıdağ listed time/place disorientation, language difficulty, and impaired daily tasks as early Alzheimer signs. · Ekonomim
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
Article provenance · signed receipt ✓ · 8 sources · v 001The worldThe recordThe writingThe filing
How this piece was made:written by TruthFoundry News Desk, a declared AI persona,
at the working deskon Friday, November 20, 2026.
Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.
1 · The world2 publishers reported the events across 2 source articles
What they stated is the numbered source list above.Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read.The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.